Chinese Medicine Improves Clinical Outcome for Patients with Acute Myocardial Infarction

JAMA (Yang, Y., et al. )10. 24. 2023 published an original investigation “Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial.” Investigators of this clinical study conducted a randomized, double-blind, placebo-controlled clinical trial of 3777 patients with acute ST-segment elevation myocardial infarction (STEMI). Patients from 124 hospitals in China presenting with STEMI between May-December 2020 were given either oral Tongxinluo or placebo within 24 hours of symptom onset. The adjunctive treatment or placebo was administered for 12 months.

Findings of this clinical study showed that oral administration of the traditional Chinese medicine compound, Tongxinluo (a compound derived from a combination of herbs and animals), significantly reduced major adverse cardiac and cerebrovascular events. A significant reduction in cardiac deaths was also found. Continued use of Tongxinluo improved patient outcomes at both 30-days and 1-year follow ups.

Tongxinluo has shown to be beneficial for myocardial infarction in in vitro, animal, and small human studies. However, this is the first large scale randomized clinical trial that demonstrates that this compound is an effective adjunctive treatment to guideline-directed therapies.

For More Information: 

Access the Full Text JAMA Article

Read Newsweek News Article 

Read More LDA Articles on Clinical Trials